Results 191 to 200 of about 19,943,678 (222)
Some of the next articles are maybe not open access.
Epistaxis and Dabigatran, a New Non-Vitamin K Antagonist Oral Anticoagulant
Acta Otorrinolaringologica (English Edition), 2014Dabigatran is a new non-vitamin K antagonist (VKA) anticoagulant with anti-thrombin action, with supposedly fewer haemorrhagic complications. However, there are actually no established agents to reverse its effect, nor specific coagulation time tests for monitoring it.An observational prospective study was developed, noting epidemiological, clinical ...
Francisco Javier, García Callejo +5 more
openaire +2 more sources
Non–Vitamin K Antagonist Oral Anticoagulants in the Treatment of Atrial Fibrillation
Annual Review of Medicine, 2019Atrial fibrillation (AF) increases a patient's stroke risk four- to five-fold. Anticoagulation with the vitamin K antagonist (VKA) warfarin reduces the risk of stroke by 67%, but warfarin carries a significant risk of major bleeding and has unpredictable pharmacodynamics with a narrow therapeutic window, necessitating frequent monitoring of its ...
Alexander C, Fanaroff, E Magnus, Ohman
openaire +2 more sources
Safety of non-vitamin K antagonist oral anticoagulants - coronary risks
Expert Opinion on Drug Safety, 2016Since the approval and commercialization of non-vitamin K antagonist oral anticoagulants (NOACs; apixaban, dabigatran, edoxaban, and rivaroxaban) several studies and meta-analyses have raised safety concerns regarding myocardial infarction (MI) risk among NOAC-treated patients, particularly with dabigatran.
Daniel, Caldeira +3 more
openaire +2 more sources
Non–vitamin K antagonist oral anticoagulant reversal: hope is on the horizon
The American Journal of Surgery, 2016Non-vitamin K oral anticoagulants have become an attractive alternative to warfarin when patients require anticoagulation. Until recently, one of the biggest challenges to these agents was the lack of specific reversal of their anticoagulation when bleeding occurs or urgent/emergent procedures are required.This article is a narrative review of peer ...
openaire +2 more sources
Non-Vitamin K Antagonist Oral Anticoagulants
Chest, 2014Gregory Y.H Lip +4 more
openaire +1 more source
Non-vitamin K antagonist oral anticoagulants and the management of bleeding
Medicine, 2017In recent years, non-vitamin K antagonist oral anticoagulants (NOACs) have become an increasingly popular choice in the treatment and prevention of venous and arterial thromboembolism, owing to the convenience of fixed dosing. Large Phase III studies and meta-analyses have shown that the risk of intracranial and fatal bleeding with NOACs is lower than ...
openaire +1 more source
[Reversal strategies for non-vitamin K antagonist oral anticoagulants].
Ugeskrift for laeger, 2018Non-vitamin K oral anticoagulants (NOACs) are alternatives to vitamin K antagonists and provide consistent anticoagulation with equal or better clinical outcome and no need for routine monitoring. Bleeding is a feared complication of anticoagulants. Until recently, no specific agent has been available for reversal of NOACs.
Frederik Uttenthal, Larsen +2 more
openaire +1 more source
Efficacy of non–vitamin K antagonist oral anticoagulants for Lemierre syndrome
The American Journal of Emergency Medicine, 2016Masayuki Kubota +5 more
openaire +2 more sources